Published in J Pharm Sci on June 01, 1978
Unaltered diazepam plasma binding using indwelling heparinized cannulae for sampling. Br J Clin Pharmacol (1980) 0.89
Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. Br J Clin Pharmacol (1981) 0.85
Fatty acids modulation of meal-induced variations in diazepam free fraction. Br J Clin Pharmacol (1980) 0.84
Serum protein binding of diazepam and its displacement by valproic acid in vitro. Br J Clin Pharmacol (1981) 0.84
Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol (1982) 0.81
Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther (1968) 2.09
Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci (1971) 2.08
Predictability of blood levels of gentamicin in man. J Infect Dis (1975) 2.06
Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci (1983) 1.95
Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci (1967) 1.87
Radioimmunoassay for prednisolone. Steroids (1973) 1.81
Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther (1978) 1.51
Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51
Effect of an anticholinergic agent on riboflavin absorption in man. J Pharm Sci (1972) 1.49
Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol (1995) 1.43
Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci (1972) 1.43
Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther (1974) 1.39
Estimating the accumulation of drugs. J Pharm Sci (1983) 1.37
The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther (1992) 1.30
General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci (1982) 1.28
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther (1992) 1.23
Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol (2000) 1.23
Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol (1981) 1.23
Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther (1978) 1.16
The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther (1986) 1.14
Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther (1987) 1.13
Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm (1981) 1.13
Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm (1977) 1.12
Effect of mode of administration on drug distribution in a two-compartment open system. J Pharm Sci (1969) 1.11
Modification of penicillin distribution and elimination by probenecid. Int Z Klin Pharmakol Ther Toxikol (1970) 1.10
Mechanisms of surfactant effects on drug absorption. J Pharm Sci (1970) 1.08
Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther (1979) 1.06
Hypothesis for the individualisation of drug dosage. Clin Pharmacokinet (1980) 1.05
Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur J Clin Pharmacol (1983) 1.05
Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol (2000) 1.04
Pharmacokinetics of drug action. Annu Rev Pharmacol (1972) 1.04
Pharmacokinetics of erythromycin on repetitive dosing. J Clin Pharmacol (1977) 1.04
Prediction of systemic availability from plasma-level data after oral drug administration. J Pharm Pharmacol (1973) 1.02
Influence of long-term infusions on lidocaine kinetics. Clin Pharmacol Ther (1982) 1.01
Some considerations as to the determination and significance of biologic half-life. J Pharm Sci (1971) 1.01
Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. IV. Chloramphenicol--urea system. J Pharm Sci (1966) 1.00
Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther (1978) 0.98
Effect of antacids on pH of urine. Clin Pharmacol Ther (1974) 0.98
Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol (1985) 0.97
Pharmacokinetics of bethanidine in hypertensive patients. Clin Pharmacol Ther (1975) 0.97
Drug distribution and renal failure. J Clin Pharmacol New Drugs (1972) 0.97
Food increases the bioavailability of isotretinoin. J Clin Pharmacol (1984) 0.96
The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther (1987) 0.96
Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther (1990) 0.96
Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature. J Pharm Sci (1965) 0.95
Bile salt enhancement of riboflavin and flavin mononucleotide absorption in man. J Nutr (1969) 0.95
Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose. Clin Pharmacokinet (1980) 0.95
Biopharmaceutic influences on the anticholinergic effects of propantheline. Clin Pharmacol Ther (1975) 0.92
Animal models for investigating intestinal drug absorption: various antibiotics. J Pharm Sci (1973) 0.91
Tissue binding of drugs. J Pharm Sci (1977) 0.91
Influence of first-pass effect on the systemic availability of propoxyphene. J Clin Pharmacol New Drugs (1973) 0.91
Renal clearance of carprofen in the isolated perfused rat kidney. Drug Metab Dispos (1981) 0.91
Route of administration and drug disposition. Drug Metab Rev (1974) 0.90
Effect of bile salts on gastric emptying and intestinal transit in the rat. Gastroenterology (1968) 0.90
Pharmacokinetics in clinical practice. 2. Applications. JAMA (1976) 0.89
Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J Pharm Sci (1969) 0.89
Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol (1978) 0.89
Rate-limiting barriers in intestinal absorption. Proc Soc Exp Biol Med (1972) 0.89
Pharmacokinetics in clinical practice. I. Concepts. JAMA (1976) 0.89
New method of solid-state dispersion for increasing dissolution rates. J Pharm Sci (1966) 0.88
Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J Clin Pharmacol (1982) 0.88
Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection. J Chromatogr (1987) 0.88
Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J Pharm Sci (1983) 0.88
Pulmonary disease and drug kinetics. Clin Pharmacokinet (1978) 0.88
Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos (1989) 0.88
Time-dependent change in renal clearance of bethanidine in humans. J Pharm Sci (1976) 0.88
An evolution of drug development and clinical pharmacology during the 20th century. J Clin Pharmacol (2000) 0.87
Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther (1982) 0.87
Solubilizing properties of bile salt solutions. II. Effect of inorganic electrolyte, lipids, and a mixed bile salt system on solubilization of glutethimide, griseofulvin, and hexestrol. J Pharm Sci (1966) 0.87
Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol (1988) 0.86
Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. J Pharm Sci (1972) 0.86
Route of administration and drug metabolism. Eur J Pharmacol (1972) 0.86
The clinical pharmacokinetics of quinapril. Angiology (1989) 0.86
Drug concentrations in the plasma as an index of pharmacologic effect. J Clin Pharmacol (1974) 0.85
Comparative pharmacokinetics of coumarin anticoaglulants XLI: Effect of phenobarbital on systemic availability of orally administered dicumarol in rats. J Pharm Sci (1979) 0.85
A new radioimmunoassay for haloperidol: direct measurement of serum and striatal concentrations. J Pharmacol Exp Ther (1981) 0.85
Fraction unbound in interstitial fluid. J Pharm Sci (1983) 0.85
Dissolution rates in surfactant solutions under stirred and static conditions. J Pharm Sci (1968) 0.84
Physiologic surface-active agents and drug absorption. 8. Effect of bile flow on sulfadiazine absorption in the rat. J Pharm Sci (1971) 0.84
Physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat. J Pharm Sci (1977) 0.84
Time course and dose dependence of antacid effect on urine pH. J Pharm Sci (1975) 0.84
Drug distribution in renal failure. Am J Med (1977) 0.84
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med (1996) 0.84
Drug transport. II. The effect of various cations on the passive transfer of drugs across the everted rat intestine. Biochim Biophys Acta (1970) 0.84
Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J Pharmacokinet Biopharm (1979) 0.83
Serum creatinine and drug half-lives in renal failure. JAMA (1972) 0.83
Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol (2001) 0.83
Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet (1985) 0.83
Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1988) 0.83
Rectal absorption from aspirin suppositories in children and adults. Pediatrics (1974) 0.82
Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J Pharmacokinet Biopharm (1982) 0.82
Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci (1977) 0.82
Bioavailability of aspirin from commercial suppositories. J Pharm Sci (1975) 0.82
Individualization of theophylline dosage using a single serum sample following a test dose. Pediatrics (1982) 0.82
Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives. J Clin Pharmacol (1989) 0.82
Multicompartment pharmacokinetic models and pharmacologic effects. J Pharm Sci (1969) 0.81
Pharmacokinetic analysis of concentration-time data obtained following administration of drugs that are recycled in the bile. J Pharm Sci (1984) 0.81